Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 328

The DOI matches its Crossref record; 64 of the 64 references it cites were found in a registry or an index.

Incorporation of Pazopanib in Maintenance Therapy of Ovarian Cancer

Open access
du Bois, Andreas, Floquet, Anne, Kim, Jae-Weon, Rau, Joern, del Campo, Josep M., Friedlander, Michael, Pignata, Sandro, Fujiwara, Keiichi, Vergote, Ignace, Colombo, Nicoletta, Mirza, Mansoor R., Monk, Bradley J., Kimmig, Rainer, Ray-Coquard, Isabelle, Zang, Rongyu, Diaz-Padilla, Ivan, Baumann, Klaus H., Mouret-Reynier, Marie-Ange, Kim, Jae-Hoon, Kurzeder, Christian, Lesoin, Anne, Vasey, Paul, Marth, Christian, Canzler, Ulrich, Scambia, Giovanni, Shimada, Muneaki, Calvert, Paula, Pujade-Lauraine, Eric, Kim, Byoung-Gie, Herzog, Thomas J., Mitrica, Ionel, Schade-Brittinger, Carmen, Wang, Qiong, Crescenzo, Rocco, Harter, Philipp·2014·Journal of Clinical Oncology

Abstract

Purpose: Pazopanib is an oral, multikinase inhibitor of vascular endothelial growth factor receptor (VEGFR) -1/-2/-3, platelet-derived growth factor receptor (PDGFR) -α/-β, and c-Kit. Preclinical and clinical studies support VEGFR and PDGFR as targets for advanced ovarian cancer treatment. This study evaluated the role of pazopanib maintenance therapy in patients with ovarian cancer whose disease did not progress during first-line chemotherapy. Patients and Methods: Nine hundred forty patients with histologically confirmed cancer of the ovary, fallopian tube, or peritoneum, International Federation Gynecology Obstetrics (FIGO) stages II-IV, no evidence of progression after primary therapy consisting of surgery and at least five cycles of platinum-taxane chemotherapy were randomized 1:1 to receive pazopanib 800 mg once per day or placebo for up to 24 months. The primary end point was progression-free survival by RECIST 1.0 assessed by the investigators. Results: Maintenance pazopanib prolonged progression-free survival compared with placebo (hazard ratio [HR], 0.77; 95% CI, 0.64 to 0.91; P = .0021; median, 17.9 v 12.3 months, respectively). Interim survival analysis based on events in 35.6% of the population did not show any significant difference. Grade 3 or 4 adverse events of hypertension (30.8%), neutropenia (9.9%), liver-related toxicity (9.4%), diarrhea (8.2%), fatigue (2.7%), thrombocytopenia (2.5%), and palmar-plantar erythrodysesthesia (1.9%) were significantly higher in the pazopanib arm. Treatment discontinuation related to adverse events was higher among patients treated with pazopanib (33.3%) compared with placebo (5.6%). Conclusion: Pazopanib maintenance therapy provided a median improvement of 5.6 months (HR, 0.77) in progression-free survival in patients with advanced ovarian cancer who have not progressed after first-line chemotherapy. Overall survival data to this point did not suggest any benefit. Additional analysis should help to identify subgroups of patients in whom improved efficacy may balance toxicity (NCT00866697).

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2014.55.7348

Cites

64 of 64 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 64 references

Cited by

See all 328

Metadata

Authors
du Bois, A., Floquet, A., Kim, J.-W., Rau, J., del Campo, J. M., Friedlander, M., Pignata, S., Fujiwara, K., Vergote, I., Colombo, N., Mirza, M. R., Monk, B. J., Kimmig, R., Ray-Coquard, I., Zang, R., Diaz-Padilla, I., Baumann, K. H., Mouret-Reynier, M.-A., Kim, J.-H., Kurzeder, C., Lesoin, A., Vasey, P., Marth, C., Canzler, U., Scambia, G., Shimada, M., Calvert, P., Pujade-Lauraine, E., Kim, B.-G., Herzog, T. J., Mitrica, I., Schade-Brittinger, C., Wang, Q., Crescenzo, R., & Harter, P.
Venue
Journal of Clinical Oncology
Published
2014-10-20
Volume
32
Issue
30
Pages
3374-3382
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2133537644
Cited by
328
References
64
FWCI
45.84
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Incorporation of Pazopanib in Maintenance Therapy of Ovarian Cancer. https://app.cochat.ai/papers/10.1200/jco.2014.55.7348
The paper
du Bois, A., Floquet, A., Kim, J.-W., Rau, J., del Campo, J. M., Friedlander, M., Pignata, S., Fujiwara, K., Vergote, I., Colombo, N., Mirza, M. R., Monk, B. J., Kimmig, R., Ray-Coquard, I., Zang, R., Diaz-Padilla, I., Baumann, K. H., Mouret-Reynier, M.-A., Kim, J.-H., . . . Harter, P. (2014). Incorporation of Pazopanib in Maintenance Therapy of Ovarian Cancer. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2014.55.7348

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.